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 2 
Abstract  1 
Background: There is limited data available on the efficacy of cortisone injection for 2 
glenohumeral osteoarthritis (GHOA). The amount and longevity of pain relief provided by a 3 
single cortisone injection is unclear. Additionally, it remains uncertain how the severity of 4 
radiographic GHOA and patient reported function and pain levels impact the efficacy of 5 
injection. Therefore, we sought to describe relief provided by a single, image guided 6 
glenohumeral injection for patients with GHOA. Additionally, we hypothesized that patients 7 
with more severe radiographic GHOA and poorer baseline shoulder function would require 8 
earlier secondary intervention.  9 
Methods: Patients with symptomatic GHOA who elected to receive a corticosteroid injection for 10 
pain relief were prospectively enrolled. A phone interview was conducted to record baseline OSS 11 
and VAS scores prior to the injection, as well as at months 1, 2, 3, 4, 6, 9, and 12. Endpoints 12 
were designated when patients required a second injection, progressed to surgery, or reached 13 
month 12. Patients were grouped by their respective baseline OSS (mild, moderate/severe) and 14 
Samilson-Prieto radiographic classification (mild, moderate, severe) for analysis.  15 
Results: Thirty shoulders (29 patients) were analyzed. 52% of patients were male. The average 16 
age of 66.1 years. No significant difference was seen in overall survival (defined as no additional 17 
intervention) between groups based on either OSS or Samilson-Prieto grades. Additionally, OSS 18 
and VAS scores at each follow-up were compared to baseline. For the entire cohort, a clinically 19 
significant difference was seen between baseline and months 1-4 for OSS and between baseline 20 
and months 1-4, 6,9, and 12 for VAS. 21 
Discussion: This study aimed to determine the efficacy of corticosteroid injections for GHOA. 22 
There were no differences in the need for secondary interventions in this population based on 23 
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severity of either the OSS or the Samilson-Prieto radiographic classification. However, patients 24 
with more severe shoulder dysfunction based on OSS did experience a statistically significant 25 
greater symptomatic relief compared with patients with milder dysfunction. Additionally, 26 
following a single injection, patients in this cohort experienced statistically and clinically 27 
relevant improvements in shoulder function and pain up to 4 months post-injection.  28 
 29 
Level of evidence: Level IV; Case Series; Treatment Study  30 
 31 
Keywords: Corticosteroid Injections, Image-Guided, Glenohumeral Osteoarthritis, Samilson-32 
Prieto classification, Oxford Shoulder Score, Visual Analog Scale  33 
 34 
 35 
 Level 1 and 2 studies on the use of corticosteroid injections in the non-operative 36 
management of glenohumeral osteoarthritis (GHOA) are lacking.7 Because of this, the American 37 
Academy of Orthopaedic Surgeons (AAOS) has been unable to make recommendations for or 38 
against the use of corticosteroid injections for GHOA in their published clinical practice 39 
guidelines.15 Previous studies have shown intra-articular injections to be safe for the treatment of 40 
osteoarthritis in other large joints.10 However, these studies have not been performed exclusively 41 
on the shoulder, nor have they given us data on the success of corticosteroid injections on 42 
delaying the need for secondary intervention, either repeat corticosteroid injections or total 43 
shoulder arthroplasty. Additionally, it is unknown if the severity of radiographic GHOA or the 44 
patient’s subjective shoulder pain and function, as documented by VAS pain score and patient 45 
reported outcomes (PROS), affect the efficacy and longevity of a glenohumeral corticosteroid 46 
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injection for arthritis. These gaps in our understanding limit our ability to provide adequate 47 
counseling to patients regarding the usefulness of corticosteroid injections as a non-operative 48 
treatment for GHOA.  49 
 Previous studies have attempted to evaluate the benefit of corticosteroid injections on 50 
shoulder pain.3,16,17 However, the usefulness of these studies is limited by their heterogeneity, 51 
including varying sources of shoulder pain (AC joint arthritis vs adhesive capsulitis), differing 52 
methods of corticosteroid injections, retrospective nature, and their small sample sizes. The lack 53 
of image-guided injections in many of these studies is of particular concern, as previous studies 54 
have concluded that image-guided corticosteroid injections are more accurate than blind 55 
injections, and they may provide longer symptomatic relief in patients with shoulder pathology.1, 56 
11 Moreover, the available data does little to help us predict which patients will have limited, 57 
short lived improvement in their symptoms, and which patients, if any, will enjoy a robust, long 58 
lasting response. 59 
 We hoped to bridge some of the gaps in our knowledge surrounding conservative 60 
management of GHOA with corticosteroid injections by establishing a protocol that allows for 61 
accurate, image-guided glenohumeral corticosteroid injection and monthly patient follow-up 62 
using validated questionnaires for pain and shoulder function. We believe that our study will 63 
provide data on the amount and duration of pain relief to expect from a single corticosteroid 64 
injection for GHOA.  65 
A second aim of this study is to evaluate the reliability of radiographic GHOA severity 66 
and validated shoulder function questionnaires in predicting the amount and duration of pain 67 
relief patients may expect from a single injection. We hypothesized that those patients with (1) 68 
more severe radiographic osteoarthritis based on the Samilson-Prieto classification and (2) poor 69 
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baseline Oxford Shoulder Scores (OSS) would require earlier secondary intervention with either 70 
repeat injections or surgical intervention.  71 
 72 
Materials and Methods  73 
 Twenty-nine patients (30 shoulders) were prospectively enrolled in an observational 74 
study following institutional review board approval and patient informed consent.  We included 75 
shoulders that met these inclusion criteria:  adults (>18 years old) with radiographically 76 
documented, symptomatic GHOA, who were indicated for a corticosteroid injection as initial 77 
treatment of GHOA. Additionally, only patients who could cognitively consent to participate in 78 
the study and continue monthly communication through phone interviews were included. 79 
Patients <18 years old, and those with inflammatory arthritis, rotator cuff tear arthropathy, 80 
significant cervical spine abnormalities, and those with shoulder pain but without GHOA were 81 
excluded.  82 
 Patients were classified using two methods: Oxford Shoulder Score (OSS) questionnaire 83 
to classify subjective shoulder function and the Samilson-Prieto classification system to classify 84 
radiographic severity of osteoarthritis. The Samilson-Prieto classification system grades arthritis 85 
as follows: Grade 0 (normal), Grade I (humeral neck osteophytes <3mm, mild), Grade II 86 
(osteophytes 3mm-7mm, moderate), and Grade III (osteophytes >7mm, severe). The radiographs 87 
of each shoulder were independently graded by a board-certified orthopedic surgeon sub-88 
specializing in surgery of the upper extremity and an orthopedic surgery resident. When there 89 
was disagreement between independent observers, we used the grade given by the attending 90 
surgeon.  91 
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The OSS questionnaire consists of a series of twelve questions. A score of 0-4 was given 92 
for each patient response, and a cumulative score between 0-48 was calculated; the higher the 93 
score, the better the shoulder function. Mild, moderate, and severe shoulder dysfunction was 94 
determined by an initial OSS between 30-48, 20-29, and 0-19, respectively.5, 6 Patients with 95 
moderate and severe shoulder dysfunction were combined in the study to improve sample size 96 
for comparison.  97 
 Patients were identified in clinic by obtaining standard shoulder radiographs. Those who 98 
agreed to participate in the study were scheduled for image-guided glenohumeral corticosteroid 99 
injections. Prior to the injection, patients were contacted over the phone in order to obtain a 100 
baseline OSS (0-48) and Likert (VAS) pain score (0-10). The anticipated injection date for each 101 
patient was then recorded. Subsequent phone interviews were conducted in a similar manner, and 102 
OSS and VAS scores were recorded at the following intervals: Month 1 (within 2 weeks of the 103 
image-guided injection), 2, 3, 4, 6, 9, and 12. The endpoint of the study occurred when patients 104 
required subsequent intervention with another corticosteroid injection, shoulder arthroplasty, or 105 
after 12 months from the initial injection. For patients who underwent a second intervention 106 
(cortisone injection or shoulder arthroplasty), we used the last recorded VAS and OSS score 107 
prior to the intervention for the remainder of the time points. This methodology was chosen to 108 
avoid artificially improving or worsening the PROS by the results of the second intervention.  109 
Statistical analysis 110 
 The collected data was imported into SYSTAT 13 and SPSS statistical analysis software 111 
and Kaplan-Meier survival plots were created. Based on the OSS, we compared the percentage 112 
of patients with mild shoulder dysfunction versus percentage of patients with moderate/severe 113 
dysfunction that did not require secondary intervention at twelve months post-injection. This was 114 
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repeated, comparing patients with mild, moderate, and severe osteoarthritis based on the 115 
Samilson-Prieto classification system. Additionally, Mann-Whitney U tests were performed to 116 
compare VAS scores between patients with mild or moderate/severe shoulder dysfunction based 117 
on the OSS at various time points, including baseline, months 1, 2, 3, 4, 6, 9, and 12. The Mann-118 
Whitney U test was repeated to determine if the VAS scores varied significantly at all time 119 
points based on the Samilson-Prieto classification. A student T-test was performed to compare 120 
the change in OSS scores from baseline to month 1 between patients with mild or 121 
moderate/severe shoulder dysfunction. The T-test was repeated to compare the change in VAS 122 
scores from baseline to Month 1 between the two groups. Lastly, a student T-test was performed 123 
to compare the change in OSS and VAS scores from baseline at each time point in the study for 124 
the entire cohort. 125 
 126 
 Results 127 
 Twenty-nine shoulders were available for analysis with one shoulder being lost to follow-128 
up at month 12. 52% of the patients were men. The average age of this cohort was 66.1 years 129 
(range= 43-86 years).  Of the twenty-nine shoulders, eight shoulders were classified as having 130 
mild osteoarthritis based on the Samilson-Prieto classification, thirteen as moderate, and eight as 131 
severe.  The inter-observer agreement was 93.3% for Samilson-Prieto grades between the two 132 
observers. Seventeen patients had mild shoulder dysfunction based on OSS, (Average score 133 
35.5) while twelve patients had either moderate or severe dysfunction (average score 21.8) 134 
(Figure 1). Additional demographic data are summarized in Table I.  135 
 The average baseline VAS score for the entire cohort was 5.8. The average VAS scores 136 
for patients with mild, moderate, and severe radiographic osteoarthritis based on the Samilson-137 
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Prieto classification were 4.9, 6.5, and 5.7, respectively. The average baseline VAS scores based 138 
on our OSS subgrouping for mild and moderate/severe shoulder dysfunction were 5.12 and 7, 139 
respectively (Figure 2). A Mann-Whitney U test was performed for VAS scores between the two 140 
groups. The VAS scores were not significantly different at any time points between the groups.  141 
 Twelve patients in the study required secondary intervention with either arthroplasty or a 142 
repeat injection prior to the end of the twelve-month study period. According to the Kaplan-143 
Meier survival analysis, 58.6% of patients for the entire cohort made it to twelve months without 144 
requiring secondary intervention overall. When analyzing our subgroups based on OSS, 64.7% 145 
of the mild group (Std. Error 11.6%, CI 95% [0.38-0.82]), and 50% of the moderate/severe group 146 
(Std. Error 14.4%, CI 95% [0.21-0.74]) made it to twelve months without requiring secondary 147 
intervention. At 6 months post injection, 82.4% of patients with mild shoulder dysfunction did 148 
not require secondary intervention (Std. Error 9.2%, CI 95% [0.55-0.94]), and 83.3% of patients 149 
in the moderate/severe group did not require secondary intervention (Std. Error 10.8% CI 95% 150 
[0.48-0.96]). To further compare the survival distributions, we utilized a Log Rank analysis (a 151 
nonparametric hypothesis test to compare the survival distributions of two samples) and failed to 152 
show a difference in overall survival curves between the two groups (p=0.446).  153 
 A Kaplan-Meijer survival analysis was also performed for patients with mild, moderate, 154 
and severe osteoarthritis based on the Samilson-Prieto classification. Patients with mild 155 
radiographic osteoarthritis had an 87.5% chance of not requiring a second intervention at twelve 156 
months (Std. Error 11.7%, CI 95% [0.39-0.98]). Patients with moderate radiographic 157 
osteoarthritis had a 46.2% chance of not requiring a secondary intervention at twelve months 158 
(Std. Error 13.8%, CI 95% [0.19-0.70]). Patients with severe radiographic osteoarthritis had a 159 
62.5% chance of not requiring secondary intervention at twelve months (Std. Error 17.1%, CI 160 
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95% [0.23-0.86]). A Log rank analysis failed to show a difference in the survival curves between 161 
groups (p=0.08).  162 
 The student T-test was performed to compare the change in OSS scores from baseline to 163 
month 1 after the injection. The mean increase in OSS in the mild group following the injection 164 
was 6.2. The mean increase in OSS in the moderate/severe group following the injection was 165 
12.8. The increase from baseline to month 1 was found to be significantly higher in the 166 
moderate/severe group when compared to the mild group (p=0.03, CI 95% [1.37-11.9]). A T-test 167 
was repeated, comparing the change in VAS scores from baseline to month 1 after the injection. 168 
The average improvement in VAS in the moderate/severe group was 3.4, whereas the average 169 
improvement in VAS in the mild group was 2.4. This was not found to be significant (p=0.32, CI 170 
95% [-1.21-2.99]).  171 
 The change in OSS scores from baseline was calculated for the entire cohort at each time 172 
point. A student T-test was then used to compare the change in OSS scores from baseline, which 173 
did show a significant difference in the mean at month 1, 2, 3, and 4. The difference was not 174 
significant at months 6, 9, and 12. This was compared against the Mean Clinically Important 175 
Difference for the OSS of 3.3, as defined by Xu et. al.14 This data showed an improvement in the 176 
OSS above the MCID during months 1-4 with the change in OSS falling below the MCID during 177 
months 6, 9, and 12 (Figure 3). 178 
 The change in VAS scores from baseline was calculated at each time point. A student T-179 
test was used to compare the change in VAS scores to baseline. This showed a statistically 180 
significant change in the mean at months 1, 2, 3, 4, 6, 9, and 12. The change in VAS was 181 
compared against the MCID for VAS of 1.4, which has been defined in previous studies.12, 13 182 
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This demonstrated improvements in VAS above the MCID for the entirety of the study (Figure 183 
4).  184 
 185 
Discussion   186 
The goal of this study was to determine the efficacy of a single, image-guided 187 
corticosteroid injection in the conservative management of GHOA and determine the magnitude 188 
of symptom relief as well longevity. We also wanted to determine whether subjective shoulder 189 
dysfunction and or radiographic severity of GHOA impacted the amount and duration of 190 
symptom relief.  191 
 To accomplish this, we developed a protocol to provide standardized, image-guided 192 
glenohumeral injections. We felt this was important for several reasons. Soh et al found that 193 
patients who underwent image-guided injections had statistically significant improvements in 194 
their shoulder pain at 6 weeks compared with patients who had blind injections.11 Additionally, 195 
image-guided glenohumeral injections have been found to be better at achieving intra-articular 196 
needle placement. Aly et al performed a systematic review which compared the accuracy of 197 
image-guided versus blind injections surrounding the shoulder girdle. They found that image-198 
guided injections into the glenohumeral joint were 92.5% accurate, whereas blind injections were 199 
only 72.5% accurate.1 200 
 In this study, there was no significant difference in the number of patients who underwent 201 
secondary intervention with a steroid injection vs total shoulder arthroplasty in the mild or 202 
moderate/severe groups based on the OSS. Additionally, radiographic severity of the GHOA 203 
based on the Samilson-Prieto classification did not impact the duration of pain relief to expect 204 
from a single injection. However, the value of “survival” to evaluate the efficacy of an injection 205 
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may be limited, due to the multiple factors involved when indicating a patient for total shoulder 206 
arthroplasty, including both patient and surgeon factors. Of note, no formal guidelines were 207 
provided to participating surgeons regarding timing of TSA following injection. There is some 208 
concern that cortisone injection increases the risk of infection following TSA. It is our general 209 
practice to avoid TSA within 3 months of an injection; this also has impacts on usefulness of 210 
“survival”.18   211 
The OSS is a validated questionnaire that gives shoulder surgeons an indication how 212 
patients are doing functionally.5 Additionally, VAS is a validated score that has been used to 213 
monitor changes in patient’s pain with rotator cuff disease as well as patients following shoulder 214 
arthroplasty.12, 13 We used both OSS and VAS in this study to get an overall appreciation of how 215 
patients were doing both functionally and symptomatically following the injection. Recently, Xu 216 
et. al. sought to determine the MCID for the OSS. In their paper, they published the results on 217 
over 300 patients following arthroscopic rotator cuff repair and followed them for 24 months 218 
post operatively. They were able to determine that the MCID for the OSS was 3.3 (95% CI [2.1-219 
4.6]) at 12 months post operatively.14 Given these results, we were able to extrapolate the MCID 220 
to be 3.3 for our study cohort. 221 
Importantly, we were able to illustrate that a single image-guided corticosteroid injection 222 
can improve the average OSS from baseline to above a MCID for 4 months (Figure 3). This 223 
suggests that the image guided corticosteroid injection did provide clinically significant 224 
improvements in shoulder function up to 4 months post-injection. Additionally, we were able to 225 
show that patients with worse baseline OSS scores may expect more functional improvements 226 
than patients with milder disease from a single corticosteroid injection. However, some of this 227 
could be a result of the ceiling effect of the OSS questionnaire.2 Regardless, these findings can 228 
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prove useful when counseling patients on what to expect from a single injection and help manage 229 
patient expectations.   230 
 A prior study by Tashjian et al, determined the MCID for the VAS score for patients with 231 
rotator cuff disease and for patients who underwent shoulder arthroplasty to be 1.4.12, 13 We 232 
extrapolated this MCID to our cohort. Based on our results, the average VAS score did remain 233 
below baseline for the entirety of the study, and, somewhat surprisingly, that improvement was 234 
greater than the MCID throughout 12 months, suggesting that this difference was clinically 235 
significant (Figure 4).   236 
 One interesting finding was that patients with severe radiographic GHOA, on average, 237 
had lower baseline VAS scores and had a trend towards a higher survival based on our Kaplan-238 
Meier survival analysis when compared with moderate radiographic GHOA. This could be 239 
coincidental given the relatively small sample size, or it could represent lower functionality, 240 
older age, or more comorbidities in this population; this again points to the limitations of using 241 
“survival” while evaluating the results of a cortisone injection. Nevertheless, radiographic 242 
severity of disease did not predict the duration of pain relief to expect from an image-guided 243 
corticosteroid injection in this study. There may be some concern that patients presenting with 244 
severe GH OA and glenoid bone loss will sustain progression of bone loss during non-operative 245 
management. No specific guidance was provided to study surgeons regarding this; rather, each 246 
surgeon could use her or his own judgement when counseling patients regarding injection. 247 
 One of the strengths of this study is its prospective, cohort design, which can provide 248 
strong evidence in the absence of a randomized controlled trial.19 Additionally, follow-up in this 249 
cohort was excellent. We were able to maintain contact with 28/29 patients (29 shoulders) for 12 250 
months following the injection. Another strength is the standardization of our injection protocol. 251 
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By only using image-guided injections and limiting our study to only patients with GH OA, 252 
potentially confounding factors were eliminated. Finally, our study includes not only 253 
radiographic measures, but also patient reported outcomes of function and pain.  254 
 There were several limitations of to this study. First, our sample size is small. Increasing 255 
the sample size may have improved the chances at finding a statistically significant difference in 256 
survival curves between study groups and decreased the chances at a possible type II error.  257 
Additionally, there was no evaluation of other modalities patients were concurrently using to 258 
treat their arthritis, such as physical therapy or NSAIDs. Also, we did not examine possible 259 
confounders, most notably the presence of a concomitant rotator cuff tear. However, it has been 260 
suggested that the likelihood of a rotator cuff tear in the setting of primary GHOA is low.4, 8 No 261 
patients had rotator cuff arthropathy. Additional comorbidities such as diabetes, hypothyroidism, 262 
fibromyalgia, etc. could have a potential impact on subjective pain and function. 263 
 264 
Conclusion 265 
 In conclusion, this study sought to prospectively determine the efficacy of a single, 266 
image-guided corticosteroid injection. To accomplish this, we used a validated shoulder survey 267 
and VAS scores obtained prospectively at routine intervals after injection in patient with 268 
radiographically confirmed GH OA. Patients in this cohort experienced statistically and 269 
clinically significant improvements in their shoulder function (OSS) for 4 months post injection, 270 
with dwindling effects thereafter. Additionally, these patients reported statistically and clinically 271 
significant improvements in their pain (VAS) for up to a year, most pronounced over the first 4 272 
months. However, either baseline OSS severity, or radiographic severity of GHOA predicted the 273 
amount of pain relief patients can expect from a single, image-guided glenohumeral injection. 274 
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These results may help shoulder surgeons counsel their patients on the duration and amount of 275 
pain relief to expect from a single, image-guided steroid injection. Additional larger, prospective 276 
studies, potentially performed in a randomized fashion with a control group, will be helpful to 277 
draw more definite conclusions on the efficacy of cortisone for GH OA. 278 
 279 
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Figure and Table Legends: 341 
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Oxford Shoulder Score 346 
Figure 4: Kaplan-Meijer survival curve comparing the 12-month survival from secondary 347 
intervention for patient with mild, moderate, and severe radiographic shoulder arthritis based on 348 
the Samilson-Prieto Classification  349 
Figure 5: Monthly change in the OSS from baseline vs MCID 350 
Figure 6: Monthly change in VAS from baseline vs MCID 351 
Figure 7: Average OSS change from baseline through months 12 for the entire cohort 352 
Figure 8: Average VAS change from baseline through month 12 for the entire cohort 353 
Table I: Patient demographics, including the following: Age, Sex, Laterality, Samilson-Prieto 354 
classification, Oxford Shoulder Score Group, Mild or Moderate/severe 355 
Table II: Average change in the OSS from baseline for months 1, 2, 3, 4, 6, 9, 12.  This change 356 
was above the MCID for months 1-4, falling below the MCID during months 6, 9, and 12.  357 
Table III: Average change in VAS from baseline for months 1, 2, 3, 4, 6, 9, and 12. This change 358 
was above the MCID for all time points in the study.  359 
29 shoulders / 28 patients Average 
Age 66.1 y/o   (range= 43-86 years) 
Sex 52% Male 
Laterality 59% Right-Sided 
Samilson-Prieto Classification  
Class I 8/29 (27.5%) 
Class II 13/29 (45.0%) 
Class III 8/29 (27.5%) 
Oxford Shoulder Score Classification  
Mild 17/29 (58.6%) 




























Average VAS at Follow-Up
























































































Change VAS over time 
Change VAS
MCID
